Stock Markets August 3, 2026 04:21 PM

Clorox Raises Annual Sales Outlook on Strength in Health and Hygiene Demand

Company cites ongoing stock-up behavior for essentials despite cost pressures and uncertain macro backdrop

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
CLX

Clorox projected 2027 net sales above Street forecasts, driven by stronger demand in health, wellness and international markets. The maker of Pine-Sol and other household brands reported mixed fourth-quarter results with sales slightly down year-on-year but beating estimates, while margins contracted and management warned of continuing cost volatility and value-seeking consumers.

Clorox Raises Annual Sales Outlook on Strength in Health and Hygiene Demand
CLX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Clorox raised its 2027 net sales outlook to a 13%-14% increase, above the 12.8% analysts expected - impacts consumer staples and household products sectors.
  • Fourth-quarter revenue fell 2% to $1.95 billion but beat estimates of $1.90 billion; adjusted EPS was $1.66 versus $1.65 expected - relevant to equity investors following consumer staples earnings.
  • Company is expanding health and hygiene exposure after acquiring GOJO Industries for $2.25 billion in April, affecting health-care-adjacent and hygiene product markets.

Clorox on Monday raised its full-year sales outlook, saying it now expects 2027 net sales to climb between 13% and 14%, a pace that exceeds the 12.8% increase analysts had modeled. Management attributed the stronger top-line trajectory to healthier demand in its health and wellness categories and improved interest from international customers, even as the broader economy remains uncertain.

Executives pointed to persistent consumer buying of essential household goods as a tailwind. Shoppers continued to replenish items such as surface cleaners, disinfectants and paper napkins, supporting revenue for brands in Clorox's portfolio.

For the quarter ended June 30, Clorox recorded sales of $1.95 billion, a 2% decline from the year-earlier period but above analysts' consensus of $1.90 billion. On an adjusted basis, the company reported quarterly earnings of $1.66 per share, narrowly topping the $1.65-per-share estimate.

Despite the revenue beat and the raised sales outlook, profitability showed pressure. The company's quarterly gross margin contracted by 520 basis points to 41.3%, a material margin compression that management flagged alongside broader cost volatility. CEO Linda Rendle cautioned that the operating environment is expected to remain challenging, emphasizing ongoing cost swings and a consumer base that remains price-conscious.

Clorox reaffirmed guidance for adjusted earnings per share for fiscal 2027 in a range of $5.70 to $6.00, versus the analysts' consensus of $5.97 per share. The company is also expanding its presence in health and hygiene following its April acquisition of GOJO Industries, the maker of Purell, which it purchased for $2.25 billion.


Taken together, the results and updated forecasts paint a picture of a company benefiting from resilient demand for essential cleaning and hygiene products while navigating margin pressure and a cautious consumer. The numbers underline a mixed near-term outlook: sales momentum has improved, but cost dynamics and value-seeking behavior among shoppers present ongoing headwinds.

Risks

  • Operating environment remains challenging with continued cost volatility, which could pressure margins and profitability - impacts corporate margins and consumer staples sector.
  • A value-seeking consumer could weigh on volume or pricing power if shoppers pursue lower-cost alternatives or trade down - impacts retail demand and branded household goods companies.

More from Stock Markets

Australian Vanadium, Alcoa to Study Large-Scale Vanadium Flow Battery Deployment in Western Australia Aug 3, 2026 Londian Wason Seeks Up to $1.7 Billion Valuation in Proposed U.S. IPO Aug 3, 2026 Grab Lifts 2026 Revenue Outlook, Backed by Promotions, Platform Expansion and Buyback Aug 3, 2026 Eli Lilly Opens Limited Early Access Pathway for Experimental Obesity Drug Retatrutide Aug 3, 2026 Aston Martin creditors warn of legal challenge after planned sale of branding rights surfaces Aug 3, 2026